Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
NCT00178256
Completed
A treatment study is being conducted by the University of Rochester Cancer Center (URCC) in which patients with non-small cell lung cancer will be treated with radiation therapy and a drug called paclitaxel. Paclitaxel is a natural product with anticancer properties. The first purpose of this study is to determine the dose of paclitaxel which, when given in combination with radiation therapy, will provide the greatest effect have the least side effects. To determine this, patients will be put on... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2015
Locations: University of Rochester, Dept. Radiation Oncology, Rochester, New York
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
TAXUS Libertē Post Approval Study
NCT00997503
Completed
The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen. This study will also contribute patient data to an FDA-requested and industry-sponsored research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT Stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2015
Locations: Advanced Cardiac Specialists, Mesa, Arizona +81 locations
Conditions: Coronary Artery Disease
Register for Updates
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
NCT00004092
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different regimens of combination chemotherapy and comparing them to see how well they work in treating patients with high-risk primary stage II or stage III breast cancer.
Gender:
ALL
Ages:
60 years and below
Trial Updated:
07/07/2015
Locations: Banner Good Samaritan Medical Center, Phoenix, Arizona +1 locations
Conditions: Breast Cancer
Register for Updates
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
NCT00421889
Completed
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in ovarian and bladder cancer patients The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer patients. Enrollment of ovarian patients is complete.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Gynecologic Oncology Associates, Newport Beach, California +10 locations
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Register for Updates
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
NCT00873119
Completed
The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Florida Cancer Specialists, Fort Myers, Florida +22 locations
Conditions: Carcinoma of Unknown Primary
Register for Updates
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
NCT00798252
Completed
To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic solid tumors
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/03/2015
Locations: Usc/Norris Comprehensive Cancer Center, Los Angeles, California +4 locations
Conditions: Advanced Cancer
Register for Updates
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
NCT01298011
Completed
The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2015
Locations: TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona +3 locations
Conditions: Resectable Pancreatic Cancer
Register for Updates
Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
NCT01011075
Completed
This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
06/06/2015
Locations: University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico +2 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
NCT00005078
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining tirapazamine, carboplatin, and paclitaxel in treating patients who have advanced malignant solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2015
Locations: City of Hope Medical Center, Duarte, California +3 locations
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer
NCT00176241
Terminated
This study seeks to establish the safety of gemcitabine, paclitaxel and low-dose radiation in recurrent, metastatic head and neck cancer through a two-stage dose escalation study, first with Gemcitabine dose escalation and then with low-dose radiation escalation. Treatment Schedule Treatment will be administered on an inpatient or outpatient basis. * Gemcitabine:2000 to 3000mg/m2 IV (in the vein) on days 1 and 15 every 28 days over 30-60 minutes. * Paclitaxel: 150 mg/m2 IV(in the vein)on days... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2015
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Head and Neck Cancer
Register for Updates
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT01281150
Completed
This phase I clinical trial studies the side effects and the best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with locally advanced or metastatic solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by blocking them from dividing. Giving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2015
Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania +2 locations
Conditions: Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Register for Updates
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
NCT00535119
Completed
This phase I trial is studying the side effects and best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with advanced solid cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with carbopl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2015
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +6 locations
Conditions: Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
Register for Updates